Literature DB >> 18363956

Cardiac manifestations of Anderson-Fabry disease in children and adolescents.

Christoph Kampmann1, Christiane M Wiethoff, Catharina Whybra, Frank A Baehner, Eugen Mengel, Michael Beck.   

Abstract

AIM: Fabry disease (Fabry) is a rare X-linked disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A. The progressive accumulation of the major substrate, globotriaosylceramide, leads to renal dysfunction and hypertrophic cardiomyopathy, which are reported to become apparent in the third decade. This study was performed to determine if signs of cardiac manifestations of Fabry are seen in younger Fabry patients.
METHODS: Twenty children and adolescents of <or=18 years of age with confirmed Fabry underwent a standard 12-lead electrocardiogram (ECG), a 2-h Holter ECG, blood pressure measurements and a two-dimensional echocardiogram. Follow-up examinations were conducted for 14 patients after a mean interval of 25.9 months.
RESULTS: At baseline, mean left ventricular mass (LVM) indexed to height (LVM/h(2.7)) was 45.0+/-2.3 and 47.0+/-3.4 g/m(2.7) in boys (n=8) and girls (n=12), respectively, and all patients had LVM/h(2.7) of >75th percentile of that in healthy controls. After a mean 26-month follow-up, 12 out of 14 patients (85.7%) showed a mean increase of 7.5+/-3.2 g/m(2.7) in LVM/h(2.7). Heart rate variability (HRV) analyses revealed that male, but not female, Fabry patients had significantly reduced HRV, reflecting a reduction in parasympathetic stimulation of the heart (p<0.05).
CONCLUSION: Cardiac involvement in children with Fabry is frequent and may progress even at young age.

Entities:  

Mesh:

Year:  2008        PMID: 18363956     DOI: 10.1111/j.1651-2227.2008.00700.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  25 in total

Review 1.  Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.

Authors:  Saskia M Rombach; Bouwien E Smid; Gabor E Linthorst; Marcel G W Dijkgraaf; Carla E M Hollak
Journal:  J Inherit Metab Dis       Date:  2014-02-04       Impact factor: 4.982

Review 2.  Genetic Infiltrative Cardiomyopathies.

Authors:  Mary E Sweet; Luisa Mestroni; Matthew R G Taylor
Journal:  Heart Fail Clin       Date:  2018-04       Impact factor: 3.179

3.  Early cardiac changes in children with anderson-fabry disease.

Authors:  Stepan Havranek; Ales Linhart; Zuzana Urbanova; Uma Ramaswami
Journal:  JIMD Rep       Date:  2013-04-02

Review 4.  Genetics and metabolic cardiomyopathies.

Authors:  E C Wicks; P M Elliott
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

Review 5.  Renal complications of Fabry disease in children.

Authors:  Behzad Najafian; Michael Mauer; Robert J Hopkin; Einar Svarstad
Journal:  Pediatr Nephrol       Date:  2012-08-17       Impact factor: 3.714

6.  Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests.

Authors:  Marieke Biegstraaten; Ivo N van Schaik; Wouter Wieling; Frits A Wijburg; Carla E M Hollak
Journal:  BMC Neurol       Date:  2010-06-07       Impact factor: 2.474

Review 7.  Fabry disease-often seen, rarely diagnosed.

Authors:  Björn Hoffmann; Ertan Mayatepek
Journal:  Dtsch Arztebl Int       Date:  2009-06-26       Impact factor: 5.594

Review 8.  Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Authors:  Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 9.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

10.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.